Victor Mangas Sanjuan-rekin lankidetzan egindako argitalpenak (13)

2023

  1. Characterization of the interplay between different biological factors driving tumor growth dynamics in the absence of treatment.

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

  3. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

2021

  1. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

  2. The role of mathematical models in immuno-oncology: Challenges and future perspectives

    Pharmaceutics, Vol. 13, Núm. 7

2018

  1. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

    European Journal of Pharmaceutical Sciences, Vol. 117, pp. 193-203

  2. Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits

    European Journal of Pharmaceutical Sciences, Vol. 120, pp. 123-132

  3. Systematic modeling and design evaluation of unperturbed tumor dynamics in xenografts

    Journal of Pharmacology and Experimental Therapeutics, Vol. 366, Núm. 1, pp. 96-104

2016

  1. Population pharmacokinetic model of lithium and drug compliance assessment

    European Neuropsychopharmacology, Vol. 26, Núm. 12, pp. 1868-1876

  2. Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects

    British Journal of Clinical Pharmacology, pp. 92-107

2015

  1. Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid

    European Journal of Pharmaceutical Sciences, Vol. 74, pp. 86-94

  2. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules

    Journal of Pharmacology and Experimental Therapeutics, Vol. 354, Núm. 1, pp. 55-64

  3. Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients

    European Journal of Pharmaceutical Sciences, Vol. 73, pp. 57-63